Inceptionr LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM

Inceptionr LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 4,558 shares of the company’s stock, valued at approximately $421,000.

Other hedge funds have also recently bought and sold shares of the company. Cullen Frost Bankers Inc. purchased a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $32,000. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $33,000. Finally, Summit Securities Group LLC purchased a new position in shares of Mirum Pharmaceuticals in the first quarter valued at approximately $42,000.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 2,721 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the sale, the senior vice president directly owned 3,114 shares of the company’s stock, valued at $373,680. The trade was a 46.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the transaction, the chief financial officer owned 42,181 shares in the company, valued at $5,156,627.25. This represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 65,315 shares of company stock worth $6,991,928 in the last ninety days. 8.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MIRM. Raymond James Financial reiterated a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Evercore reiterated an “outperform” rating and issued a $138.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Royal Bank Of Canada boosted their target price on Mirum Pharmaceuticals from $142.00 to $148.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $143.40.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $113.03 on Monday. The stock has a market cap of $6.89 billion, a PE ratio of -8.30 and a beta of 0.48. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The stock’s fifty day moving average is $108.77 and its two-hundred day moving average is $100.52. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company’s revenue was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.30) EPS. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.